We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

China is to lead a massive international research project to describe all the proteins in the human liver — the liver proteome — under the auspices of the Human Proteome Organisation (HUPO).

Controversially, as part of the project, a Beijing team hopes to generate a huge collection of monoclonal antibodies and provide them to scientists around the world at cost price. These antibodies are usually made one at a time, and HUPO is concerned both because the plan may be over-ambitious and because antibody production has not yet been standardised.

China has already pledged 200 million yuan (US$24 million) for the three-year pilot phase of the international liver-proteome study.

Link to full Nature article

Reference: Nature 425, 441 (2003)